Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback